Jack Silberstein
Chief Executive Officer & Founder Deck Bio
Jack aims to engineer a designer immune checkpoint inhibitor with significantly enhanced binding affinity for specific immune inhibitory ligands as a way of blocking inhibitory signaling in T cells. With this targeted approach, Jack hopes to more effectively block cancer’s immunosuppression, thereby maximizing the therapeutic potential of immune checkpoint blockade.
Seminars
Tuesday 23rd June 2026
Synchronizing Global Regulatory Strategies by Navigating Non-Clinical Discrepancies to Expedite Global Approval of Next-Generation TCEs
2:00 pm
Join this workshop to navigate the shifting regulatory landscape for non-clinical safety, where the focus moves from traditional animal-heavy packages to a weight of evidence framework.
- Discussing policy inconsistencies across health authorities regarding animal usage, focussing on non-human primate studies
- Exploring ‘weight of evidence’ approaches for well-established or characterized targets to potentially waive or refine studies
- Debating scientific examples such as the necessity of repeated NHP studies for new generations of B-cell depleting CD3 T-cell engagers
- Uncovering the possibility of referencing marketed products for weight of evidence studies
- Advancing the idea of a ‘bridging study’ via in vitro comparative data rather than a full GLP NHP study when a new molecule only has slightly modified Fc regions
Wednesday 24th June 2026
Panel Discussion: Translating Mechanistic Insights into Effector Durability through Mitigating T-Cell Exhaustion
12:30 pm
- Analyzing whether mass changes in peripheral T-cell capacity serve as a predictive biomarker for clinical response r a signature of therapeutic failure
- Identifying points where TCEs fail to maintain sustained cytotoxic pressure and harnessing these insights to inform the timing of TCE administration
- Understanding how chronic antigen exposure under TCE stimulation drives effector dysfunction and how these findings can be used to engineer more resilient T-cell therapies
Wednesday 24th June 2026
Expanding the Reach of T Cell Engagers in Solid Tumors through pMHC Multi-Targeting
11:30 am
- Addressing the fundamental challenge of low pMHC copy number and target heterogeneity that limits TCE efficacy in solid tumors through multi-pMHC recognition strategies
- Demonstrating how engineered TCRs can recognize multiple cancer-restricted pMHCs through shared structural motifs, enabling potent T cell activation at sub-10 pM EC50s while maintaining specificity
- Establishing comprehensive specificity de-risking approaches using sequence-agnostic, immunopeptidomics-based screening across >13,000 healthy tissue peptides to support broad application across major solid tumor indications
